Akèy › Kansè Metastatik › Michigan › Detroit
Etid klinik pou Kansè Metastatik nan Detroit, MI
24 etid pou Kansè Metastatik ap chèche patisipan nan sit nan ak bò kote Detroit (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Ap rekriteFaz 2/3
- Henry Ford Cancer- Detroit, Detroit
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Ap rekriteFaz 3
- Research Site, Detroit
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Ap rekriteFaz 1/2
- Henry Ford Cancer Institute, Detroit
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Ap rekriteFaz 1
- Karmanos Cancer Institute, Detroit
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ap rekriteFaz 3
- Karmanos Cancer Institute, Detroit
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Ap rekriteFaz 3
- Karmanos Cancer Institute, Detroit
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Clinical Study Site, Detroit
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 2
- Henry Ford Cancer Institute/Henry Ford Health System, Detroit
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Ap rekriteFaz 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Ap rekriteFaz 1/2
- Crinetics Study Site, Detroit
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Ap rekriteFaz 1
- Henry Ford Hospital, Detroit
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Investigative Site #120, Detroit
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Henry Ford Health System, Detroit
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Henry Ford Hospital, Detroit
Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases
Ap rekrite
- Henry Ford Hospital, Detroit
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Ap rekriteFaz 1/2
- Henry Ford Cancer Institute, Detroit
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Ap rekriteFaz 3
- Henry Ford Health System, Detroit
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Ap rekriteFaz 1/2
- Karmanos Cancer Institute, Detroit
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Ap rekriteFaz 1/2
- Karmanos Cancer Institute, Detroit
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Ap rekriteFaz 1
- Henry Ford Cancer Center, Detroit
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Ap rekriteFaz 1
- Henry Ford Cancer Institute, Detroit
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
Ap rekriteFaz 1
- Karmanos Cancer Institute, Detroit
A Beta-only IL-2 ImmunoTherapY Study
Ap rekriteFaz 1/2
- Karmanos Cancer Institute, Detroit
Etid Kansè Metastatik nan lòt vil
- Houston, TX104 etid
- New York City, NY93 etid
- Nashville, TN70 etid
- Boston, MA63 etid
- Los Angeles, CA57 etid
- St. Louis, MO54 etid
- Arlington, VA53 etid
- Philadelphia, PA46 etid
- Chicago, IL45 etid
- San Antonio, TX44 etid
- Washington, DC43 etid
- Dallas, TX42 etid
Lòt etid nan Detroit
- Kansè Poumon ki pa ti selil44 etid
- Kansè nan tete33 etid
- Kansè (tout kalite)29 etid
- Kansè kolorektal26 etid
- Kansè ovè26 etid
- Kansè pwostat22 etid
- Kansè Endomèt21 etid
- Kansè poumon20 etid
- Myelom Miltip19 etid
- Kansè lestomak16 etid
- Karsinòm selil skuamèz tèt ak kou15 etid
- Leksemi mieloïd egi14 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.